Ambry Unveils New Neurodevelopmental Genetic Testing

Customers now may order a suite of five genetic tests for neurodevelopmental conditions from Aliso Viejo, Calif.-based Ambry Genetics.

Ambry’s new tests offerings are:

• IDNext: a broad panel of 140 genes known to be associated with both syndromic and non-syndromic intellectual disability;
• AutismFirst: a targeted panel of 16 genes recognized by the American College of Genetics and Genomics as associated with syndromic ASDs;
• AutismNext: a broader panel of 48 genes that can cause both syndromic and non-syndromic ASDs;
• Neurodevelopment-Expanded: a broad panel of 196 genes designed for patients who have a combination of ID, ASDs, and epilepsy; and
• Rett/AngelmanNext: a panel of 22 genes known to cause symptoms of multiple overlapping neurodevelopmental disorders, including Rett syndrome and Angelman syndrome.

According to numbers cited by the company, neurodevelopmental disorders affect more than 4.6 million Americans. — Elizabeth Hollis